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Abstract: Among many mycotoxins, T-2 toxin, macrocyclic trichothecenes, fumonisin B1 
(FB1) and ochratochin A (OTA) are known to have the potential to induce neurotoxicity in 
rodent models. T-2 toxin induces neuronal cell apoptosis in the fetal and adult brain. 
Macrocyclic trichothecenes bring about neuronal cell apoptosis and inflammation in the 
olfactory epithelium and olfactory bulb. FB1 induces neuronal degeneration in the cerebral 
cortex, concurrent with disruption of de novo ceramide synthesis. OTA causes acute 
depletion of striatal dopamine and its metabolites, accompanying evidence of neuronal cell 
apoptosis in the substantia nigra, striatum and hippocampus. This paper reviews the 
mechanisms of neurotoxicity induced by these mycotoxins especially from the viewpoint 
of oxidative stress-associated pathways. 
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1. Introduction 
Mycotoxins are fungal metabolites known to be harmful toward human and animal health. To   
date, disorders caused by mycotoxins have been reported in digestive, urinary, immune and 
reproduction systems [1], and many in vivo and in vitro studies have been performed in order to clarify 
the mechanisms of mycotoxin-induced toxicity in these systems. Recently, Surai et al. [2] described 
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that, in many cases, membrane-active properties of various mycotoxins determine their toxicity and 
incorporation of mycotoxins into membrane structures causes various detrimental changes, resulting in 
alterations in second messenger systems through damaging membrane receptors. In addition, 
detrimental effects of mycotoxins on DNA and RNA and protein synthesis together with proapoptotic 
action further compromise important metabolic pathways and consequently changes in physiological 
functions including growth, development and reproduction occur. During the last decades, the 
importance of oxidative stress and lipid peroxidation in all these processes have been pointed out by 
many researchers [2,3]. 
Compared with the amount of research on digestive, urinary, immune and reproduction systems, 
there are few reports of the effects of mycotoxins on neuronal tissues. This paper reviews the 
mechanisms of neurotoxicity experimentally induced in rats and mice by T-2 toxin, macrocyclic 
trichothecenes, fumonisin B1 (FB1) and ochratoxin A (OTA) especially from the viewpoint of 
oxidative stress-associated pathways. 
2. T-2 Toxin 
T-2 toxin is a cytotoxic secondary fungal metabolite that belongs to thetrichothecene mycotoxin 
family. They are produced by various species of Fusarium (F. sporotichioides, F. poae, F. equiseti, 
and  F. acuminatum), which can infect corn, wheat, barley and rice crops in the field or during   
storage [4,5]. T-2 toxin is conjectured to be a major factor in alimentary toxic aleukia in humans [6] 
and has been implicated in additional mycotoxicoses such as red mold disease in humans and   
animals [7] and beanhull poisoning in horses [8]. 
T-2 toxin is a well-known inhibitor of protein synthesis through its high binding affinity to peptidyl 
transferase which is an integral part of the 60 s ribosomal subunit [9–11]. Subsequent inhibition of the 
peptidyl transferase reaction can trigger a ribotoxic stress response that activates c-Jun N-terminal 
kinase (JNK)/p38 mitogen-activated protein kinases (MAPKs) [11]. Moreover, T-2 toxin interferes 
with the metabolism of membrane phospholipids and increases liver lipid peroxides [12,13]. 
Oral, parenteral and cutaneous exposures to T-2 toxin induce lesions in hematopoietic, lymphoid 
and gastrointestinal tissues and suppress reproductive functions in domestic and laboratory   
animals [14–17]. T-2 toxin can induce apoptosis in many types of cells bearing rapid rates of 
proliferation [18–22]. T-2 toxin also induces apoptosis and fatty change in hepatocytes of mice 
following the increased expression of both oxidative stress- and apoptosis-related genes (c-fos and  
c-jun) [23]. Moreover, prenatal exposure of rats to T-2 toxin induces apoptosis in maternal liver, 
placenta and fetal liver following the increased expression of oxidative stress- and apoptosis-related 
genes and decreased expression of lipid metabolism- and drug-metabolizing enzyme-related genes in 
these tissues [24]. Doi et al. [25,26] have reviewed the mode of occurrence and mechanisms of T-2 
toxin-induced apoptosis in mice and rats. 
To date, the effects of T-2 toxin on the central nervous system (CNS) have received limited 
attention [27], and therefore, there are only a small number of reports of T-2 toxin-induced 
neurotoxicity [28–30]. Boyd et al. [28] reported that low levels of T-2 toxin were responsible for the 
changes in the metabolism of brain biogenic monoamines, and Wang et al. [31] showed that ingestion 
of T-2 toxin leads to changes in amino acid permeability across the blood-brain barrier, which could Int. J. Mol. Sci. 2011, 12  5215 
 
 
lead to neurological effects observed in animals exposed to trichothecenes. T-2 toxin may be easily 
distributed to the fetal brain, and induce fetal death and fetotoxicity mainly in the CNS and skeletal 
system in addition to maternal toxicity [32–35]. 
Sehata et al. [36] have investigated the mechanisms of apoptosis induction in the fetal brain by oral 
administration of T-2 toxin (2 mg/kg b.w.) to pregnant rats on day 13 of gestation. In their study, the 
number of apoptotic neural progenitor cells in the telencephalon increased from 1 h and peaked at  
12 h after T-2 toxin treatment. Microarray analysis revealed that the expression of heat shock protein 
70 (HSP70), metallothionein (MT)-2 and 1, and heme oxygenase-1 (HO-1) was strongly elevated by 
T-2 toxin at 12 h, and the expression of the Cu, Zn-superoxide dismutase (Cu, Zn-SOD) gene also 
increased at 24 h after T-2 toxin treatment. This suggests that oxidative stress might be the main factor 
behind the T-2 toxin-induced changes in the fetal brain. In addition, the gene expression of   
liver stearyl-CoA desaturase and farnesyl diphosphate synthase genes which are involved in lipid 
metabolism was suppressed by T-2 toxin in the fetal brain [36]. 
T-2 toxin suppresses drug metabolizing enzymes such as glutathione S-transferases (GSTs) [36–38]. 
In addition, a decreased expression in mitochondria-related genes, such as mitochondrial   
NADH-dehydrogenase and cytochrome oxidase, has been reported in the fetal brain [36], suggesting a 
dysfunction of the mitochondria. Since mitochondria play an important role in cell survival, these 
changes in metabolism-related genes may also have a relationship to the induction of apoptosis. 
In the study by Sehata et al. [36] on the fetal brain, the expression of MEKK1 gene increased at 12 
and 24 h, and the expression of c-jun gene at 24 h after T-2 toxin treatment. These findings suggest 
that the MAPK-JNK-c-jun pathway might be involved in T-2 toxin-induced apoptosis in the fetal 
brain. Extracellular signal-related protein kinase (ERK) mediates cell growth and protects cells   
from apoptosis, whereas stress-activated protein kinase (SAPK)/JNK and p38 MAPK inhibit cell 
proliferation and may promote apoptosis [39]. Each MAPK is activated by an upstream MAPK kinase, 
including MEKK1, and JNK activates transcription factors such as c-fos and c-jun. MEKK1 may 
induce apoptosis by causing a general deregulation of MAPK signaling [40], and JNK and c-jun are 
important regulators of apoptosis in the nervous system [41].  
Differing from the results in the maternal liver, placenta and fetal liver [24], the increase in   
caspase-2 gene expression with no changes in caspase-9 and Bax-α gene expression was detected in 
the fetal brain at 24 h after T-2 toxin treatment [36], suggesting an involvement of caspase-2 activation 
in T-2 toxin-induced apoptosis in the fetal brain. Activation of caspase-2 is induced by reactive oxygen 
species (ROS), and caspase-2 is said to play a crucial role in the control of apoptosis [42–44]. 
Although it is suggested that the p53-related mitochondrial pathway is involved in the T-2   
toxin-induced apoptosis in the maternal and fetal livers [24], apoptosis induction in the fetal brain by 
T-2 toxin seems to be independent of the p53-related pathway which is the most important pathway in 
DNA-damaging agent-induced apoptosis of neural progenitor cells in the developing brain [45–49]. 
In microarray analysis on the fetal rat brain from dams exposed to T-2 toxin, the expression of 
vascular endothelial growth factor (VEGF) gene increased at 12 and 24 h after T-2 toxin   
treatment [36]. VEGF is expressed in neurons and may play a role in the maintenance of neurons and 
endothelial cells in the CNS [50]. Therefore, the observed VEGF induction in the fetal brain might 
indicate a protective reaction to the apoptotic changes in the fetal brain induced by T-2 toxin.  Int. J. Mol. Sci. 2011, 12  5216 
 
 
Recently, Chaudhary and Rao [27] evaluated acute toxicity of dermal and subcutaneous exposure of 
T-2 toxin on brain oxidative stress in adult mice. Mice were exposed to LD50 of T-2 toxin either by the 
dermal (5.94 mg/kg b.w.) or subcutaneous (1.54 mg/kg b.w.) route and sacrificed at 1, 3 and 7 days 
post-exposure. They reported that T-2 toxin-treated animals showed a time-dependent increase in ROS 
generation, glutathione (GSH) depletion, lipid peroxidation and protein carbonyl content in the brain in 
both routes of exposure. The gene expression profile of antioxidant enzymes showed a significant 
increase in SOD and catalase via the percutaneous route and glutathione reductase (GR) and 
glutathione peroxidase (GPx) via the subcutaneous route. This indicates that T-2 toxin induces 
oxidative damage in adult mouse brain as well as in fetal rat brain. Lipid peroxidation may bring about 
protein damage and inactivation of membrane-bound enzyme either through direct attack by free 
radicals or through chemical modification by its end products [51]. Indeed, as mentioned above, 
protein carbonylation, a sign of oxidative damage, significantly increased in the mouse brain after 
exposure to T-2 toxin.  
Chaudhary and Roa [27] also investigated the role of nuclear factor erythroid 2-related factor (Nrf2) 
and its downstream targets of phase II antioxidant/detoxifying enzymes in the mouse brain exposed to 
T-2 toxin. Upon activation, Nrf2 binds to antioxidant responsive element sites in the promoter regions 
of many detoxification and antioxidant genes, leading to coordinate regulation of downstream targets 
that boost the cellular detoxification process and antioxidant potential [52,53]. In the study of 
Chaudhary and Roa [27], however, Nrf2 and its downstream target genes were down-regulated, and  
the involvement of Nrf2 in augmenting oxidative potential is not significant, although there is   
oxidative stress. 
3. Macrocyclic Trichothecenes 
The fungus Stachybotrys chartarum, a saprophyte that grows on wet cellulose-containing building 
materials including wallboard, ceiling tiles and cardboard is often found in low concentrations among 
the mycoflora identified in water-damaged buildings [54–57]. Chronic indoor exposures to S. 
chartarum and its products or components have been postulated to etiologically contribute to damp 
building-related illnesses (DBRI) such as debilitating respiratory [58,59] and nonrespiratory symptoms 
involving immune and neurological impairment [56,60–62]. Experimental rodent studies revealed   
that, while this fungus is not infectious, airway exposure to spores of S. chartarum and its components 
have the potential to evoke toxicity, inflammation and allergic sensitization in the upper and lower 
respiratory tracts [56]. 
Two toxic “chemotypes” of S. chartarum exist. One chemotype elaborates highly toxic macrocyclic 
trichotecene mycotoxins whereas a second chemotype produces less toxic atranones and simple 
trichothecenes but no macrocyclic trichothecenes [63]. The former mycotoxins are potent translational 
inhibitors and stress kinase activators that appear to be a critical underlying cause for a number of 
adverse effects. Notably, these toxins form covalent protein adducts in vitro and  in vivo and, 
furthermore, cause neurotoxicity and inflammation in the nose and brain of the mouse [64,65]. On the 
other hand, the latter mycotoxins can induce pulmonary inflammation. Pestka et al. [56] have reviewed 
the relationship between S. chartarum,  trichothecene mycotoxins, and DBRI and proposed new 
insights into a public health enigma. Int. J. Mol. Sci. 2011, 12  5217 
 
 
Besides inhibiting translation, macrocyclic trichothecenes as well as other trichothecenes can 
simultaneously activate p38, JNK and ERK and MAPKs in vivo and in vitro [66–68] via a process 
referred to as “ribotoxic stress” [69]. In cell cultures, macrocyclic trichothecenes (Type D 
trichotecenes) are 10–100 times more potent than Type A (e.g., T-2 toxin) or Type B (e.g., 
deoxynivalenol) trichothecenes at activating MAPKs, impairing leukocyte proliferation, or inducing 
apoptosis [11,70–75]. The common ability of macrocyclic trichothecenes to cause protein synthesis 
inhibition via binding to the 18S rRNA of the ribosomal large subunit [76] has been speculated to be a 
major mechanism underlying induction of cell apoptosis by this group of trichothecenes. Moreover, the 
potential of macrocyclic trichothecenes to covalently bind to proteins and possibly other 
macromolecules has major implications relative to their absorption, metabolism, distribution, toxicity, 
and potential allergenicity [64,65]. 
Satratoxin G (SG) is one of the most potent macrocyclic trichothecenes produced by S. chartarum [75] 
and contributes to the above-mentioned DBRI. Roridin A (RA) is a commercially available 
macrocyclic trichithecene used as a SG surrogate, and roridin L2 (RL2) is a putative biosynthetic 
precursor of SG. While SG contains an intact macrocyclic ring linking C-4 to C-15, the precursor RL2 
contains only an extended carbon chain linked at C-4 [77]. RL2 is said to be nontoxic [78]. Satratoxin 
H (SH) is another macrocyclic trichothecene mycotoxin derived from the fungus S. chartaum. This 
mycotoxin is one of the toxic constituents of the toxic mushroom, Podostoma cornu-damae [79]. 
Murine alveolar type II cells and alveolar macrophages are extremely sensitive to intratracheally 
instilled  S. chartarum spores [80]. The methanol extract of a trichothecene-producing strain of   
S. chartarum particularly up-regulates DNA damage-responsive and DNA repair genes in the murine 
alveolar macrophage cell line MH-S early in the treatment, which are suggestive of genotoxic   
stress [81]. In a follow-up study, extract-induced apoptosis in MH-S cells was observed to precede 
DNA damage [82]. Moreover, both p38- and p53-mediated signaling events seem to occur in   
S. chartarum-induced apoptosis of alveolar macrophages. 
Macrocyclic tricothecenes also affect the upper respiratory tract (e.g., nasal airway). Using an 
intranasal instillation model in adult C57BL/6J mice, Islam et al. [83] showed that SG exposure 
specifically induced apoptosis of the olfactory sensory neurons (OSNs) and subsequent atrophy of the 
olfactory epithelium (OE). Concurrently, there was bilateral atrophy of the olfactory nerve layer of the 
olfactory bulbs (OBs) of the brain. In addition, SG induced an acute, neutrophilic rhinitis   
and encephalitis. Similar findings have also been reported in mice intranasally instilled with RA [84]. 
In the ethmoid turbinates and OBs in the frontal brain in mice treated with SG, elevated   
mRNA expression for the proinflammatory cytokines, TNF-α, IL-6 and IL-1, the chemokine   
macrophage-inflammatory protein-2 (MIP-2), and the proapoptotic genes, Fas, FasL, p75NGFR, p53, 
Bax, caspase-3 and CAD, was detected at 24 h post instillation (PI). In the same regions of mice 
treated with RA, up-regulated mRNA expression of Fas, TNF-α, IL-6 and IL-1 and MIP-2 was 
observed from 6 to 24 h PI, whereas expression of several other proapoptotic genes (p53, Bax, and  
caspase-activated DNase) was detectable only at 24 h PI. 
Following intranasal instillation of mice to SG [83] or RA [84], double-stranded RNA-activated 
protein kinase (PKR) mRNA concentrations in the nasal turbinates were up-regulated in parallel with 
OSN apoptosis. PKR, Bax and p53 have been previously reported to mediate apoptosis in murine Int. J. Mol. Sci. 2011, 12  5218 
 
 
OSNs [85–87]. PKR associates with the ribosome [88] and can selectively shut down translation   
via phosphorylation of eukaryolic initiation factor 2α (eIF2α) as well as activate NF-κB [89]. 
Both TNF-α and Fas directly induce apoptosis in OE [90] and in OE organ cultures [91,92], and 
SG- and RA-induced TNF-α and Fas mRNA expression precedes or is concurrent with OSN apoptosis, 
induction of caspase-3 mRNA and caspase-3 activation [83,84]. The origins of induced TNF-α are 
considered to be OSNs and adjacent cells in the OE which would promote autocrine or paracrine 
responses, respectively. SG and RA also directly induces apoptosis in the OSNs by initiating 
mitochondrial cell death via an intrinsic pathway involving p53 and Bax. Islam et al. [93] used the 
PC12 rat pheochromocytoma cell models to elucidate potential mechanisms of SG-induced neuronal 
cell death. In their experiment, SG-induced apoptosis occurred at 48 h after SG treatment, and the 
expression of p53, and PKR, Bax and caspase-activated DNase mRNAs was significantly elevated 
from 6 to 48 h after SG treatment. SG-induced p53 and Bax gene expression is known to drive nuclear 
translocation of apoptosis-inducing factor (AIF), mitochondrial flavoprotein, in PC-12 cells [93]. 
In the study by Islam et al. [93], SG-induced apoptosis was not affected by inhibitors of oxidative 
stress or MAPKs but was suppressed by the PKR inhibitor C16 and by PKR siRNA transfection. PKR 
inhibition also blocked SG-induced apoptotic gene expression and AIF translocation but not caspase-3 
activation. These results indicate that SG-induced apoptosis in PC12 neural cells is mediated by PKR 
via a caspase-independent pathway possibly involving AIF translocation. 
SH is thought to induce caspase-3 activation and apoptosis of PC12 cells through the activation of 
p38 MAPK and JNK in a GSH-sensitive manner [94]. Moreover, Nusuetrong et al. [79] carried out the 
study to further elucidate the mechanisms by which SH induces cell death in PC12 cells. They reported 
that SH causes apoptosis of serum-deprived PC12 cells within 24 h and that SH increases ROS 
production and lipid peroxidation which are attenuated by incubation of cells with GSH. They 
suggested that SH-induced increase in apoptosis of serum-deprived PC12 cells, may be partially 
mediated through the generation of ROS. GSH, the most abundant intracellular thiol, plays an 
important role in controlling the redox state of cells, and GSH is thought to play a role in apoptotic cell 
death following its efflux through the GSH-specific membrane channels, carrier-mediated GSH 
extrusion and oxidative stress [79,95]. 
The constant activation of inflammatory and apoptotic pathways at low levels of exposure in human 
neurological system cells may amplify devastation to neurological tissues and lead to neurological 
system cell damage from indirect events triggered by the presence of SH [96]. This suggests that 
individuals exposed to SH and microbial organisms resulting in a chronic immune response 
(inflammation and oxidative stress) could have increased sensitivity to these agents, leading to neural 
damage, further supporting previous in vivo studies demonstrating CNS tissue damage via inhalation 
of fungal toxins [97]. The process of inflammation is intended to repair injured tissues; however, this 
mechanism tends to induce damage to nervous tissues when activated [98,99]. In this context, studies 
on canines by Caldeón-Garcidueñas et al. [100,101] demonstrated increased iNOS, NF-κB, and TNF-α 
production among other inflammatory and oxidative stress agents—leading to permanent damage of 
DNA and CNS tissues due to passage of small particles via olfactory epithelium and lung tissue. The 
fine particles reach CNS tissue via the olfactory bulb and into brain tissue (frontal cortex and cortical 
tissues) demonstrating increases in β-amyloid plaques suggestive of pathogenesis similar to 
Alzheimer’s disease [100,101]. Int. J. Mol. Sci. 2011, 12  5219 
 
 
4. Fumonisin B1 
Fumonisins belong to the relatively recently discovered group of mycotoxins produced by the 
fungus Fusarium verticillioides (formerly F. moniliforme), a widespread fungal concomitant of various 
cereals, predominantly corn [2,102]. In this case, FB1 is the most abundant and toxic; it has been linked 
to a number of diseases in humans and animals [102,103]. 
The structures of FB1 and sphingolipids show marked similarities, which may be the reason why 
FB1 drastically disrupts the normal sphingolipid metabolism [104]. FB1 inhibits ceramide synthase, a 
key enzyme in de novo sphingolipid biosynthesis and sphingolipid turnover, causing elevated levels of 
free sphingolipid bases and sphingolipid base metabolites and lowered levels of ceramide [105,106]. 
FB1-induced inhibition of ceramide synthesis can result in a wide spectrum of changes in lipid 
metabolism and associated lipid-depending signaling pathways, and it appears to be a major 
contributor to the carcinogenic and other deleterious effects of FB1 [106]. 
FB1 is well known to cause equine leukoencephalomalacia (ELEM) [107,108]. This disease is 
associated primarily with FB1 and is characterized by high mortality [108]. In histopathological 
examinations, pathognomonic focal necrotic lesions, located primarily in the subcortical white matter 
are apparent [102]. In addition, the elevation of free sphingoid bases after FB1 treatment has been 
demonstrated in the brain of ELEM-diagnosed horses [109], suggesting that free sphingoid bases may 
be important in FB1-related neurotoxicity.  
Another emerging neurodevelopmental aspect of FB1 toxicity that implicates the consumption of 
fumonisins in the etiology of neuronal tubule defects (NTD) in children has recently been   
suggested [110]. Treatment with FB1 causes NTDs in ex vivo neurulating mouse embryos [111] and 
this effect is related to the folic acid receptor deficiency as a result of the FB1-dependent lipid rafts 
depletion [112]. 
The detrimental effects of FB1 on neuronal tissue have been shown in a number of reports indicating 
its potential for direct neurotoxicity. For example, FB1 drastically inhibits axonal growth in cultured 
hippocampal neurons [113], increases levels of sphinganine concentration in the forebrain and brain 
stem of rats accompanying a concomitant demyelination in the forebrain [114], and disrupts 
myelination in glial cells but not neurons in aggregating brain cell culture [115] and in developing  
rats [116]. FB1-dependent changes in neurotransmitter metabolite levels in different brain regions   
of BALB/c mice [117] and in rat brain [118], and alteration of electrophysiological activity in rat 
neocortex [199] are also reported.  
Osuchowski et al. [120] carried out a study to compare the toxicity of FB1 in mouse brain after an 
intracerebroventricular (icv) or subcutaneous (sc) infusion with total doses of 0, 10 or 100 μg/kg of 
FB1. The icv infusion of FB1 led to neuronal degeneration in the cortex, concurrent with disruption of 
sphingolipid metabolism, i.e., inhibition of de novo ceramide synthesis, stimulation of astrocytes, and 
activation of proinflammatory cytokine signaling while the sc infusion of FB1 brought about partial 
inhibition of sphingolipid metabolism in the cortex. From these results and the reports showing that 
FB1 compromises the endothelial barrier function [121,122], it is suggested that there may be limited 
blood-brain barrier transfer of FB1 [123] and that FB1 may disrupt central nervous system homeostasis 
when brain tissue is directly exposed to this mycotoxin. Int. J. Mol. Sci. 2011, 12  5220 
 
 
All cytokines analyzed in the study of Osuchowski et al. [120] are CNS-borne and are expressed 
on-site by neurons (IL-1β and IL-6), astrocytes (IL-1β, IL-6, TNF-α and interferon-γ; IFN-γ) and 
microglia (IL-1β, IL-6 and TNF-α) [124]. IL-1β, IL-6 and TNF-α are primarily associated with 
neuronal injury; thus neuronal damage will be accompanied by their elevated expression. In addition, 
the increased expression of TNF-α and IL-1β also indirectly enhance neuronal damage via  
ceramide-mediated signaling, since both cytokines activate brain neutral sphingomyelinase (nSMase), 
and the role of ceramide-dependent neurodegeneration mediated by nSMase is reported [125,126]. The 
immunocompetent cells and proinflammatory signaling are first being activated (i.e., astrocytes and 
probably microglia) and then neurodegeneration follows in mouse brain after FB1 infusion [120]. 
During the last decades, studies aimed at clarifying the mechanisms of FB1-induced neurotoxicity in 
cultured cells has been done mainly from the viewpoints of oxidative stress and/or apoptosis. 
Stockmann-Juvala et al. [127] tried to characterize oxidative stress-related parameters induced by FB1 
in three different neural cell lines, human SH-SY5Y neuroblastoma, rat C6 glioblastoma and mouse 
GT1-7 hypothalamic cells. In their study, FB1 caused a dose-dependent increase of ROS production in 
C6 and GT1-7 cells but was without an effect in SH-SY5Y cells. Decreased GSH levels, increased 
malon dialdehyde (MDA)-formation, indicative of lipid peroxidation, and necrotic cell death were 
observed in all cell lines after incubation with FB1. From these results, they concluded that FB1 
induces oxidative stress in human, rat and mouse neural cell cultures. They also suggested that FB1 is 
cytotoxic to neural cells only at high concentrations in vitro, although systemic toxicity, which may be 
caused by the inhibition of ceramide synthase, takes place already at very low concentrations of   
FB1 [104].  
Mobio et al. [128–130] reported that in rat C6 glioma cells, FB1 inhibits protein synthesis, causes 
DNA fragmentation and cell death, increases 8-hydroxy-2’-deoxyguanosine (8-OH-dG), and induces 
lipid peroxidation, and that cytotoxic concentrations of FB1 induce cell cycle arrest in C6 cells (in the 
G2/M phase after 24 h and in G0/G1 after 48 h incubation with FB1), possibly associated with 
genotoxic event. On the other hand, Galvano et al. [131,132] reported that FB1 does not increase ROS 
production or cell death in rat astrocytes although DNA-damage and caspase-3 activation take place. 
Based on these results, the authors suggested that effects of FB1 are not a result of oxidative injury, but 
are instead a response that may occur after modulation of protective genes. These theories support the 
above-mentioned observations in FB1-treated SH-SY5Y cells. In SH-SY5Y cells, lipid peroxidation 
took place without an increase in ROS production, and was associated with delayed cell death. 
Moreover, low expression of the anti-apoptotic Bcl-2 protein in GT1-7 and C6 cells can be linked  
to low basal GSH levels in these cell lines [127], and may increase their susceptibility to radical  
attack [133–135]. SH-SY5Y cells, on the other hand, express higher levels of Bcl-2 [133,136], which 
may explain why GSH levels in these cells decreased later than in GT1-7 and C6 cells exposed to FB1. 
Stockmann-Juvala  et al. [137] have also investigated the effects of FB1 on human U-118MG 
glioblastoma cells. In their study, FB1 increased lipid peroxidation and the production of ROS in   
U-118 MG cells dose- and time-dependently and these effects were accompanied by decreases in the 
GSH levels and cell viability. In addition, signs of apoptosis were indicated by increased caspase-3-
like protease activity and internucleosomal DNA fragmentation. Based on these results, they 
concluded that oxidative stress and apoptosis may be involved in the neurotoxicity induced by FB1. 
There are a number of studies showing FB1-induced apoptosis in different cell types [129–131,138–140]. Int. J. Mol. Sci. 2011, 12  5221 
 
 
Apoptosis is considered to be a common result of oxidative stress caused by ROS production, 
disturbance of GSH generation and lipid peroxidation [141,142]. In addition, activation of caspase-3 
may be one of the events causing an increase in ROS production, and subsequent lipid peroxidation 
and reduction of intracellular GSH levels. 
5. Ochratoxin A 
Ochratoxin A (OTA) is a fungal metabolite produced by Aspergillus ochraceus and Penicillium 
verrucosum. OTA is found in a variety of plant food products such as cereals. Because of its long half-
life, it accumulates in the food chain [143,144] and is frequently detected in human plasma at 
nanomolar concentrations [145,146]. OTA has been found to be involved in the developments of 
certain kidney diseases [147] and enzymuria [148] similar to Balkan endemic nephropathy found in 
humans [147,149]. In addition to nephrotoxicity, the main OTA-induced toxicity, OTA has also been 
reported to have immunotoxic [150,151], teratogenic [152,153], genotoxic [154] and neurotoxic [155] 
effects. Although there is still insufficient evidence in humans, there is sufficient evidence in 
experimental animals for the carcinogenicity of OTA [156]. 
OTA has complex mechanisms of action that include evocation of oxidative stress, bio-energetic 
compromise, mitochondrial impairment, inhibition of protein synthesis, production of DNA single-
strand breaks and formation of OTA-DNA adducts [155,157–160]. The bio-energetic compromise 
induced by OTA may be responsible for the generation of free radicals and ROS that results in global 
oxidative damage to DNA and lipids and damage to proteins through generation of oxygen free 
radicals and nitric oxide [161,162]. OTA renal toxicity and carcinogenicity may be, at least partly, 
mediated by an Nrf2-dependent signal transduction pathway [53]. Effect of OTA on potential   
signaling molecules (growth factors, fatty acids, and/or Ca2
+) could disrupt PKC-regulated pathways 
downstream, and down-regulation of genes under transcriptional control of Nrf2 may lead to a reduced 
oxidative stress response. In addition, OTA-induced down-regulation of genes under hepatocyte nuclear 
factor 4α(HNF4α)-control may affect key metabolic processes. This could make kidney cells more 
vulnerable to OTA-induced toxicity leading to tumor development [163]. OTA has also been reported to 
inhibit succinate-dependent electron transfer in the electron transport chain, but at higher concentrations 
will also inhibit electron transport at Complex I [164,165], suggesting mitochondrial toxicity.  
The developing brain appears to be very susceptible to the deleterious effects of OTA [166–169]. 
OTA has been shown to affect proliferation and migration of neurons [153] and reduce DNA   
content [170] in the developing rodent brain. OTA is also reported to be neurotoxic to adult male  
rats [166]. Neurotoxicity is more pronounced in the ventral mesencephalon, hippocampus (HP), and 
striatum than in the cerebellum (CB) [171]. Recent animal and cellular studies have suggested that 
OTA may contribute to the development of human and animal systemic problems, including 
neurodegenerative diseases and brain dysfunction [155]. 
Sava et al. [155] investigated the time course of acute effects of OTA in the context of DNA 
damage, DNA repair and global oxidative stress across six brain regions, CB, cortex (CX), HP, 
midbrain (MB), caudate/putamn (CP) and pons/medulla (PM), in male mice, and they showed that 
OTA causes acute depletion of striatal dopamine (DA) and its metabolites as well as decreased 
tyrosine hydroxylase immunoreactivity in the corpus striatum on a background of globally increased Int. J. Mol. Sci. 2011, 12  5222 
 
 
oxidative stress evidenced by significant increases in lipid peroxidation and oxidative DNA damage, 
and transient inhibition of oxidative DNA repair activity (oxyguanosine glyosylase, OGG1) across six 
brain regions, accompanying evidence for apoptosis in the substantia nigra (SN), striatum and HP or 
other regions. Unlike the monophasic SOD activation, the oxidative DNA repair response exhibited a 
biphasic response.  
Sava et al. [172] also examined the possibility that OTA can cause parkinsonism in male mice 
focusing on the effects of chronic low doses of OTA exposure on regional brain oxidative stress and 
striatal DA metabolism. They reported that continuous administration of low doses of OTA with 
implanted subcutaneous Alzet minipumps caused a small but significant decrease in striatal DA levels 
and an up-regulation of anti-oxidant systems and DNA repair. These data suggest the possibility that 
low dose exposure to OTA will result in an earlier onset of parkinsonism when normal age-dependent 
decline in striatal DA levels is superimposed on the mycotoxin-induced lesion. In their study, since the 
CP and MB showed a relatively diminished OGG1 activity and increased oxidative DNA damage, it 
was postulated that the DA terminals of the striatum would suffer damage. This concept is supported 
by an earlier report of increased oxidative DNA damage in SN and striatum in post-mortem brain from 
Parkinson’s disease cases [173] and by the above-mentioned report that acute doses of OTA caused a 
dose-dependent decrease of striatal DA and a decrease in DA turnover [155]. The regional 
vulnerability to the toxin was not directly related to the concentration of the toxin in each region. 
Moreover, as mentioned above, not all regions were equally sensitive to the toxin, even though all 
brain regions were capable of marked increases in OGG1 activity. Namely, the CP was most sensitive 
to the toxin while the CB was the least sensitive. In addition, the HP, a primary site of neurodegeneration 
in Alzheimer’s disease, turns out to exhibit relatively high OTA levels with concurrently pronounced 
OTA neurotxicity [166]. OTA may also be toxic through other mechanisms. For example, due to its 
chemical structure, OTA inhibits protein synthesis by competition with phenylalanine in the 
aminoacylation reaction of phenylalanine-tRNA [174,175] and phenylalanine hydroxylase   
activity [157], leading to the impairment of the synthesis of DOPA, dopamine and catecholamines or 
enzymes involved in the metabolism of DNA. 
The adult brain retains a reservoir of stem-progenitor cells in the hippocampal “neurogenic zone” 
capable of proliferative activity throughout life [176,177], and it is known that injury, irradiation, 
drugs and endogenous factors such as hormones and trophic factors impact neurogenesis [178–181]. 
Therefore, OTA may also impact neurogenesis in adult HP. In addition, subchronic administration of 
OTA is demonstrated to affect cognitive functions by reducing hippocampal N-methyl-D-aspartate 
(NMDA) receptor subunits 2A and 2B concentrations in rats [182]. 
Sava et al. [183] tested neural stem/progenitor cells (NSCs) prepared from HP of adult mouse  
brain for their vulnerability to OTA in vitro. OTA, added to the cultures in concentrations of   
0.01–100 mg/mL, caused a dose- and time-dependent (6–72 h) decrease in viability of both 
proliferating and differentiating NSC. Along with decreased viability, OTA elicited a pronounced 
oxidative stress evidenced by a robust increase in total and mitochondrial SOD activity, and OTA also 
significantly increased OGG1 activity. Proliferating NSC exhibited a greater vulnerability to the toxin 
than differentiated neurons despite robust DNA repair and antioxidant responses. Such a result is 
unexpected since DNA repair systems are typically more active and efficient in proliferating cells than 
in post-mitotic differentiated cells [184,185]. It suggests that OTA’s mechanism of action as an Int. J. Mol. Sci. 2011, 12  5223 
 
 
inhibitor of mitochondrial oxidative metabolism may be less critical than its interference with DNA 
synthesis and mitotic competence. Overall, Sava et al. [183] speculated that OTA exposure may 
contribute to impaired hippocampal neurogenesis in vivo, resulting in depression and cognitive 
deficits, conditions reported to be linked to mycotoxin exposure in humans [186–188]. 
Yoon et al. [189] investigated the potential harm caused by environmental exposure to OTA in 
terms of its effects on neuronal cell viability and proteome profiles using mouse hippocampal HT22 
and human neuroblastoma SH-SY5Y cells. Generation of ROS was detected in OTA-treated SH-SY5Y 
and HT22 cells, however, caspase activation and an increase in p53 phosphorylation were only 
detected in HT22 cells, even though OTA treatment caused oxidative stress in both two cell lines. The 
expressions of several proteins (valosin containing protein, propyl 4-hydroxylase, Atp5b protein, 
nucleophosmin 1, eukaryotic translation elongation factor 1 delta isoform, ornithine aminotransferase, 
prohibitin, and peroxiredoxin 6), which have been suggested to be implicated in the pathogenesis of 
neurodegenerative disorders, were up-regulated only in HT22 cells after treatment with OTA, which 
was interesting because OTA induced the apoptosis of HT22 cells but not of SH-SY5Y cells. 
Involvement of the mitochondrial dysfunction-related apoptotic process in OTA toxicity in HT22 cells 
was corroborated by the results showing significant decline in mitochondrial activity in OTA-treated 
HT22 cells, not in SH-SY5Y cells. Such differences between cell lines might be due in part to the 
complex natures of protein expression and functional regulation required during the intracellular 
signaling of apoptosis [190], and the above-mentioned alteration of protein expression profile in HT22 
cells after OTA treatment is considered to be related to ROS generation. Because inhibition of 
expression of propyl 4-hydoxylase is known to attenuate neuronal death associated with oxidative 
stress [191], ornithine has been shown to be up-regulated during ROS-related apoptotic cell death [192], 
and valosin containing protein has been proposed to contribute to the conversion of oxidative stress  
to an endoplasmic reticulum stress response during the pathological processes of a number of 
neurodegenerative disorders [193]. Contrary to the above-mentioned report by Sava et al. [183],   
Zhang et al. [194] reported that caspase-9 and caspase-3 were activated in response to OTA treatment 
and caspase inhibitors were effective in partly counteracting OTA-induced apoptosis-related 
neurocytotoxicity not only in primary rat cortical neuronal cells but also in human neuroblastoma SH-
SY5Y cells and that such OTA-induced apoptosis was accompanied by a loss of mitochondria 
membrane potential. The authors suggest that OTA may contribute to the pathogenesis of 
neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s disease) in which apoptotic processes 
are centrally involved. The reason for the difference in apoptosis-inducing ability of OTA in human 
neuroblastoma SH-SY5Y cells between the two reports still remains unclear. 
Besides the toxic effects of OTA on neuronal cells, Zurich et al. [195] investigated the relationship 
between OTA toxicity and glial reactivity in serum-free aggregating rat brain cell cultures, and they 
showed that OTA affects the cytoskeletal integrity of astrocytes as well as the expression of genes 
pertaining to the brain inflammatory response system, and suggested that a relationship exists between 
the inflammatory events and the cytoskeletal changes induced by OTA. Furthermore, they also 
suggested that, by inducing an atypical glial reactivity, OTA may severely affect the neuroprotective 
capacity of glial cells. Moreover, Hong et al. [196] reported that OTA caused concentration-dependent 
reductions in neurite outgrowth and cell number, and induced the activation of transcription factors 
activator protein-1 (AP-1) and NF-κB activation in cultured rat embryonic midbrain cells, and that  Int. J. Mol. Sci. 2011, 12  5224 
 
 
15-deoxy-delta 12, 14-prostaglandin J2 (15-deoxy PGJ2), a peroxisome proliferator-activated receptor 
gamma (PPAR-γ) agonist, blocked OTA-induced neurotoxicity by inhibiting AP and NF-κB activation 
in cultured rat embryonic midbrain cells. 
6. Conclusions 
This paper has reviewed the mechanisms of neurotoxicity induced in rodents and neuronal cell lines 
by T-2 toxin, macrocyclic trichothecenes, FB1 and OTA. 
T-2 toxin, one of the Type A trichothecene mycotoxins, triggers a ribotoxic response through its 
high binding affinity to peptidyl transferase which is an integral part of the 60 s ribosomal subunit, 
resulting in activation of JNK/p38 MAPKs. T-2 toxin also interferes with the metabolism of membrane 
phospholipids and increases liver lipid peroxides. In the fetal brain, oxidative stress is considered to be 
the main factor behind the T-2 toxin-induced changes, and the MAPK-JNK-c-jun pathway is thought 
to be involved in T-2 toxin-induced neuronal cell apoptosis. Moreover, activation of caspase-2 is 
essential to T-2 toxin-induced apoptosis in the fetal brain. T-2 toxin also induces oxidative damage in 
the adult mouse brain as well as in the fetal rat brain. 
Macrocyclic trichothecenes have been postulated to etiologically contribute to DBRI such as 
debilitating respiratory and nonrespiratory symptoms. The common ability of macrocyclic trichothecenes 
to cause protein synthesis inhibition via binding to the 18s rRNA of the ribosomal large subunit has 
been speculated to be a major mechanism underlying induction of cell apoptosis by this group of 
trichothecenes. In mice, SG or RA exposure specifically induces apoptosis of OSNs and subsequent 
atrophy of OE. SG or RA also induces apoptosis in, and atrophy of, the olfactory nerve layer of OBs of 
the brain. Moreover, in the ethmoid turbinates and OBs in the frontal brain in mice treated with SG or 
RA, elevated mRNA expression for the inflammatory cytokines, chemokine, and proapoptotic genes 
and increased mRNA concentrations for PKR are detected. In PC12 neural cells, SG-induced apoptosis 
is mediated by PKR via a caspase-independent pathway possibly involving AIF translocation from 
mitochondria to the nucleus. On the other hand, SH is thought to induce caspase-3 activation and 
apoptosis of PC12 cells through the activation of MAPK and JNK in a GSH-sensitive manner.  
FB1 is well known to cause ELEM and may be implicated in the etiology of NTD in children.  
FB1-induced inhibition of ceramide synthesis can result in a wide spectrum of changes in lipid 
metabolism and associated lipid-dependent pathways. FB1 may disrupt central nervous system 
homeostasis when brain tissue is directly exposed to this mycotoxin. Namely, the icv infusion of FB1 
leads to neuronal degeneration in the cortex, concurrent with disruption of sphingolipid metabolism, 
i.e., inhibition of de novo ceramide synthesis, stimulation of astrocytes, and activation of 
proinflammatory cytokine signaling. In in vitro studies, FB1 inhibits protein synthesis, causes DNA 
fragmentation and cell death, increases 8-OH-dG, and induces lipid peroxidation in rat C6 glioma 
cells, and oxidative stress and apoptosis may be involved in the neurotoxicity induced in human   
U-118MG glioblastoma cells by FB1. On the other hand, effects of FB1 are not a result of oxidative 
injury but are instead a response that may occur after modulation of protective genes in rat astrocyte 
and SH-SY5Y human neuroblastoma cell cultures.  
OTA has complex mechanisms of action that include evocation of oxidative stress, bio-energetic 
compromise, mitochondrial impairment, inhibition of protein synthesis, production of DNA   Int. J. Mol. Sci. 2011, 12  5225 
 
 
single-strand breaks and formation of OTA-DNA adducts. OTA causes acute depletion of striatal DA 
and its metabolites in the corpus striatum on a background of globally increased oxidative stress across 
six brain regions of rats examined, accompanying evidence for apoptosis in the SN, striatum and HP or 
other regions. The CP is most sensitive to the toxin while the CB is the least sensitive, and the HP, 
primary site of neurodegeneration in Alzheimer’s disease, turns out to exhibit relatively high OTA 
levels with concurrently pronounced OTA neurotoxicity. OTA exposure may contribute to impaired 
hippocampal neurogenesis in vivo, resulting in depression and cognitive deficits. OTA also induces 
oxidative stress and apoptosis through caspase activation and increase in p53 phosphorylation in 
various neural cell cultures. OTA seems to contribute to the pathogenesis of neurodegenerative 
diseases in humans (e.g., Alzheimer’s and Parkinson’s disease), in which apoptotic processes are 
essentially involved.  
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